Uniondale

Researchers are evaluating PET scans using radiotracers FDG and FDHT to detect the spread of prostate cancer in patients with progressive disease. This research focuses on how these scans can better identify tumor sites by comparing FDHT accumulation with conventional imaging methods and studying its relationship with androgen receptor expression. The study aims to provide early assessments of treatment outcomes by tracking changes in tracer uptake alongside disease progression markers such as PSA levels and new or enlarging lesions. Participants will undergo PET scans using either FDHT alone or a combination of FDG and FDHT depending on the clinical question. Scans are performed at baseline, week 4, week 12, and then every 12 weeks up to a year, with a maximum of eight scan sets in total. Some patients may have blood samples taken to study how FDHT moves through the body and may receive an initial dynamic scan if more pharmacokinetic data is needed, followed by whole-body imaging. During the study, researchers will assess the accumulation and distribution of FDHT at various tumor sites and compare these results with bone scans, CT, and MRI at baseline, 4 weeks, and 12 weeks. Patients will be monitored through imaging and laboratory tests to track disease progression and tracer uptake. The study involves regular imaging visits over a 12-month period to gather comprehensive data on tumor metabolism and receptor activity, supporting better understanding of prostate cancer progression and treatment response.

Researchers are evaluating whether a dietary intervention can influence treatment response and quality of life for people newly diagnosed with multiple myeloma who are receiving standard induction chemotherapy including daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). The study also explores how diet affects disease markers, the microbiome, and immune system indicators. Quality of life is measured through patient-completed questionnaires. Participants receive nutrition counseling and coaching, including optional group sessions every two weeks and text message reminders. They will be provided with 12 frozen, fixed pre-made lunches and dinners weekly for 12 weeks from Modify Health. Regular phone calls with a dietitian occur every four weeks, with a final phone or video call at the end of the induction chemotherapy. Surveys are completed before and after the intervention. During the study, participants complete various questionnaires about diet and quality of life. Researchers monitor treatment response using minimal residual disease negative complete response rates after one year. Other assessments include tracking disease, microbiome, and immune markers. The study requires participants to complete scheduled visits and surveys and allows for remote follow-up and monitoring throughout the treatment period.

Research suggests that music-based activities may improve brain functions such as attention, memory, and executive function. This study is investigating whether telehealth music therapy is a practical approach to treat cognitive difficulties experienced by survivors of blood cancers like lymphoma, leukemia, and myeloma. The study will also explore whether music therapy and music education can improve cognitive function along with symptoms like anxiety, depression, and fatigue. Participants will be assigned to one of two groups. The Music Therapy (MT) group will engage in therapeutic music lessons, guided music listening, and music-centered discussions to help regulate mood, energy, and attention and discover personally meaningful songs. The control group will receive Therapist-Attention Music Education (TAME), consisting of twelve weekly 60-minute sessions guided by board-certified music therapists with homework to reinforce concepts. Both interventions are delivered remotely through telehealth. Participants will complete assessments to measure cognitive function and related symptoms, monitored over up to one year. The main outcome is the feasibility of completing nine or more music therapy sessions. The study includes evaluations of anxiety, depression, fatigue, and cognitive symptoms using questionnaires. Safety and adherence will be tracked during the study period.

This research aims to collect real-world data on patients with lung cancer, specifically those diagnosed with Stage I non-small cell lung cancer (NSCLC), who are undergoing pulmonary segmentectomy surgery. The study focuses on understanding patient outcomes after this lung cancer surgery and tracking disease-free survival over several years. Participants are assessed using patient-reported outcome measures to capture their physical function, pain, and breathlessness. Participants will complete surveys using the Patient-Reported Outcomes Measurement Information System (PROMIS), a web-based platform from the National Institutes of Health. These surveys assess physical function, pain interference, and dyspnea severity. Questionnaires will be administered before surgery, between 2 to 4 weeks after surgery, and again 6 months after surgery. The study will also determine disease-free survival at 3 and 5 years following surgery. During the study, participants will provide information through PROMIS surveys at the specified time points. Researchers will monitor disease-free survival to evaluate long-term outcomes after lung surgery. The total participation duration includes follow-up assessments up to 5 years to measure disease-free survival. Data collected will help understand recovery and cancer outcomes for patients undergoing pulmonary segmentectomy for lung cancer.

Researchers are creating a registry to collect detailed information from people diagnosed with various types of T-cell and natural killer (NK)-cell lymphomas. This registry aims to better understand these diseases and improve outcomes for patients. The study includes a wide range of specific lymphoma subtypes based on established classification guidelines. Participants may optionally provide blood and nail samples for research and biobanking purposes. The study involves gathering clinical data and tumor specimens, including fresh or archival tumor biopsies. Those with certain lymphoma types, such as mycosis fungoides or primary cutaneous lymphomas, must be receiving systemic therapy to participate. During the study, researchers will collect clinical information and tumor samples to build a comprehensive database. They will monitor participants' health outcomes over time and use the data to enhance knowledge about T-cell lymphomas. The main outcome is the number of participants contributing to the T-cell Lymphoma Master Repository over a 10-year period. Participation does not interfere with other clinical trial involvement or treatments.

Researchers are studying how butyrate levels in stool change when people with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) follow a plant-based diet for at least 12 weeks. The study aims to compare the effects of a whole foods plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo supplements on stool butyrate levels in these participants. Participants in the study will follow one of three interventions: a whole foods plant-based diet consisting of low glycemic index meals with legumes, vegetables, whole grains, and minimally processed plant-based fats, supported by dietary education and counseling every 4 weeks for 12 weeks; algae omega-3 and curcumin supplements taken twice daily for 52 weeks; or placebo supplements taken twice daily for 25 weeks. The plant-based diet group will receive detailed meal recommendations and ongoing support from a research dietitian. During the study, participants' stool microbiome diversity will be assessed at 12 weeks to measure changes. The study involves regular monitoring and support to help participants adhere to their assigned interventions. Researchers will track dietary adherence, collect stool samples, and evaluate safety and tolerability throughout the study period.

Researchers are evaluating if combining propranolol and etodolac with mind-body resilience training (MBRT) and music therapy can help reduce physiological stress before, during, and after primary debulking surgery (PDS) or interval debulking surgery (IDS) in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. This study compares this combined approach to the standard care, which does not include specific stress reduction interventions. Participants in the study receive propranolol 20 mg twice daily and etodolac 400 mg twice daily for 21 consecutive days, starting at least 7 days before surgery. Propranolol dosing is reduced to 10 mg twice daily for 3 days postoperatively (days 14-16). Alongside the medications, participants undergo behavioral interventions including mind-body resilience training, a meditation technique aimed at achieving relaxation, and music therapy, which has been shown to reduce anxiety and sedation needs. The study focuses on stress reduction during the perioperative period. Participants will be closely monitored for their ability to complete over 80% of the bundled interventions by 21 days after surgery. Assessments include tracking adherence to drug regimens and behavioral therapies, and measuring physiological stress responses. Safety and side effects are observed throughout the study. Total participation includes the preoperative lead time, perioperative period, and follow-up until 21 days after surgery.

Researchers are evaluating whether a personalized chemoradiation therapy approach, which may use a lower dose of radiation, is as effective as the standard chemoradiation therapy for people with HPV-positive throat cancer. The study also aims to see if using a lower radiation dose with standard chemotherapy results in fewer side effects and how both treatment approaches affect participants' quality of life through questionnaires. Participants will receive chemoradiation therapy with either 30 Gy or 70 Gy of radiation combined with standard chemotherapy drugs including cisplatin, carboplatin, and 5-FU. During week two of radiation treatment, patients will undergo a single 18F-FMISO PET scan to monitor their condition. Quality of life will be assessed using questionnaires like EQ-5D-5L, MDADI-HN, and COST-FACIT. Throughout the study, researchers will monitor overall survival over two years. Participants will complete various assessments and questionnaires to measure side effects and quality of life. The study includes careful safety monitoring and follows participants for two years to evaluate treatment outcomes and effects on daily living.

Researchers are comparing different FDA-approved and NCCN-recommended drug treatments for people with high-grade non-muscle invasive bladder cancer (NMIBC). This Phase 3 trial specifically evaluates nadofaragene firadenovec against standard treatments like gemcitabine (with or without docetaxel), mitomycin, re-treatment with BCG, or pembrolizumab. The goal is to find out which treatment works better for this condition when BCG has failed. Participants randomized to the nadofaragene firadenovec group will receive this drug instilled into the bladder with normal saline every 3 months for up to 12 months. Other groups will receive standard care treatments, including weekly intravesical gemcitabine and docetaxel for 6 weeks followed by monthly maintenance for up to 24 months. These treatments are administered directly into the bladder to target the cancer cells. During the study, participants are monitored for high-grade recurrence-free survival for up to 24 months. Researchers will assess how well the treatments prevent cancer from returning during this time. The study involves regular treatment visits and follow-ups to evaluate safety and effectiveness, ensuring ongoing monitoring and care throughout the participation period.

Researchers are comparing two optical coherence tomography (OCT) devices to see how well they perform in imaging ocular tumors. OCT is a noninvasive scanning method using reflected light to create detailed images of the back of the eye. This helps doctors detect and monitor different types of eye cancers. The study focuses on adults with ocular tumors and evaluates the image quality and the field of view provided by each device. The devices being studied are the Intalight Dream OCT, a next-generation swept-source device with faster imaging speed and higher sensitivity, and the Heidelberg Spectralis OCT, which is currently the standard of care for optical imaging. Participants will undergo imaging with these devices to compare their effectiveness in capturing detailed pictures of the ocular tumors. During the study, participants must have at least one eye with an intraocular or ocular surface tumor and meet certain vision and eye health criteria. Researchers will assess image quality and field of view for up to one year. Participants need to be able to fixate on the imaging target and sit still for about two minutes during imaging. The study will monitor these outcomes to better understand the performance of each OCT device in ocular tumor imaging.